Lot of superficial analyses out there suggesting this is just a hot air balloon that will descend back to "where it belongs" once the air gets cooler. Longs know better, and so do the analysts. 110 and 1135 are very close to being totally de-risked. FDA approval is When, not If. And as a result of what AMGEN just paid for ONYX, we now have a fairly precise idea of what CLDX's near-term pipeline is worth to Big Pharma. It's well north of $45. GLTA
Investors looking for the next big investment ideas should look no further than the Russell 2000 small-cap index, Cramer told viewers. They'll find that over half of this year's biggest movers are biotechs, stocks that Cramer has championed for many years.
He said that biotechs are the quintessential anti-Washington stocks because they can prosper whether the government is open or closed.
Among the names that caught Cramer's attention were Acadia Pharmaceuticals (ACAD_), Celldex Threapeutics (CLDX_), Insys Threapeutics (INSY_), Keryx Biopharmaceuticals (KERX_), Clovis Oncology (CLVS_), Isis Pharmaceuticals (ISIS_) and NPS Pharmaceuticals (NPSP_).
Cramer said all of these names are smaller, more speculative investments, but all have the potential to become the next Celgene (CELG_) or Gilead Sciences (GILD_) and can make investors just as much money, even though they're already up huge for the year.